According to the Zhitong Finance App, Zaiding Pharmaceutical (09688) announced results for the six months ended June 30, 2026. The group achieved total revenue of US$206 million; net losses of US$102 million; and a basic loss of US$0.09 per share during the period.

R&D expenses increased by US$16 million (or 14%) to US$127 million, mainly due to an increase in licensing fees under the Group's licensing and cooperation agreements.

The Group believes that the ability to successfully develop candidate products will be a major factor affecting the Group's long-term competitiveness and future growth and development. Developing high-quality product candidates requires a long-term investment of significant resources. The Group is committed to promoting and expanding the pipeline of potentially best-in-class and potentially first-of-its-kind products, such as through clinical and pre-clinical trials and business development activities. As a result, the Group expects to continue to invest heavily in R&D, including internal discovery activities.

In June 2026, the Group launched menomellintrimonium chloride for the treatment of schizophrenia in adults in mainland China. Nomellintrazonium chloride is the first treatment for schizophrenia with a new mechanism in over 70 years. By selectively activating M1 and M4 muscarinic receptors, it provides a new method for treating schizophrenia. The Group is preparing to seek enomelin and trisodium chloride to be included in China's national health insurance catalogue in 2027.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.